MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    The results of DBS in patients with Parkinson’s disease for 10 years in Belarus

    A. Buniak, V. Alexeyevets, S. Likhachev (Minsk, Belarus)

    Objective: To study the efficiency and SE of DBS in PD patients in Republican Research and Clinical Center of Neurology and Neurosurgery in Belarus for…
  • 2022 International Congress

    The Journey Of Levodopa Treatment in Parkinson’s disease

    B. Pandey (Tirupati, India)

    Objective: This study aims to relook the journey of levodopa in the treatment of Parkinson’s disease. Background: Levodopa has been used in the treatment of…
  • 2022 International Congress

    Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report the use of levodopa-carbidopa intestinal gel (LCIG) as an additional therapy for the treatment of motor fluctuations in a patient with advanced…
  • 2022 International Congress

    GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms

    O. de Fabregues, A. Pascual-Rodríguez, M. de Lucca, M. Sellés, F. Palau, G. Fernández, J. Hoenicka (Barcelona, Spain)

    Objective: To characterize an early-onset Parkinson’s disease (EOPD) patient with atypical clinical phenotype. Background: Genome sequencing is allowing new Parkinsonian Syndromes (PS)-associated genes identification. However,…
  • 2022 International Congress

    Effects of Parkinson’s disease and freezing of gait on the kinematic and kinetic gait parameters

    D. Campos, T. Shida, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campos, Brazil)

    Objective: This study aims to evaluate the effects of Parkinson's disease and freezing of gait (FoG) on the kinematic and kinetic gait parameters, both in…
  • 2022 International Congress

    Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat

    I. Frouni, W. Kang, D. Bédard, S. Belliveau, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age

    M. Caulfield, F. Manfredsson, J. Stancati, C. Sortwell, S. Boezwinkle, M. Vanderwerp, T. Collier, K. Collier (Grand Rapids, USA)

    Objective: To advance understanding of striatal CaV1.3 (cacna1d) channel silencing as a therapeutic approach to reduce levodopa-induced dyskinesias (LID), a side effect of long-term escalating…
  • 2022 International Congress

    The effect of levodopa on speech in patients with Parkinson’s disease

    M. Mrackova, R. Marecek, J. Mekyska, M. Kostalova, R. Rektorova (Brno, Czech Republic)

    Objective: To assess levodopa-induced changes in fMRI signal in areas involved in speech production (ROIs) in PD. Evaluate association between these changes and changes in…
  • 2022 International Congress

    Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG

    T. Gurevich, A. Evans, G. Kägi, D. Koziorowksi, L. Bergmann, JC. Parra Riaza, O. Sanchez-Soliño, J. Slawek (Tel Aviv, Israel)

    Objective: To evaluate the feasibility and patient satisfaction of video-assisted telenursing as well as demonstrate resolution for treatment-related issues in the real-word levodopa-carbidopa intestinal gel…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley